

# Carole Fakhry

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4909812/publications.pdf>

Version: 2024-02-01

176  
papers

14,976  
citations

57681

46  
h-index

21843

118  
g-index

178  
all docs

178  
docs citations

178  
times ranked

14993  
citing authors

#	ARTICLE	IF	CITATIONS
1	Surgeon Volume and Laryngectomy Outcomes. <i>Laryngoscope</i> , 2023, 133, 834-840.	1.1	2
2	Neoadjuvant immunotherapy prior to surgery for mucosal head and neck squamous cell carcinoma: Systematic review. <i>Head and Neck</i> , 2022, 44, 562-571.	0.9	12
3	Head and neck cancer survivorship consensus statement from the American Head and Neck Society. <i>Laryngoscope Investigative Otolaryngology</i> , 2022, 7, 70-92.	0.6	35
4	Is 2045 Optimistic?â€”Concerns Regarding Rising Vaccine Hesitancyâ€”Reply. <i>JAMA Oncology</i> , 2022, 8, 482.	3.4	0
5	Prevalence of human papillomavirus in head and neck cancers at tertiary care centers in the United States over time. <i>Cancer</i> , 2022, 128, 1767-1774.	2.0	7
6	Validation of NRG Oncology's prognostic nomograms for oropharyngeal cancer in the Veterans Affairs database. <i>Cancer</i> , 2022, 128, 1948-1957.	2.0	3
7	Association of Plasma Circulating Tumor HPV DNA With HPV-Related Oropharynx Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2022, 148, 488.	1.2	11
8	Comparison of next generation sequencing, droplet digital PCR, and quantitative real-time PCR for the earlier detection and quantification of HPV in HPV-positive oropharyngeal cancer. <i>Oral Oncology</i> , 2022, 128, 105805.	0.8	16
9	Oral human papillomavirus prevalence, persistence, and risk-factors in HIV-positive and HIV-negative adults. <i>Tumour Virus Research</i> , 2022, 13, 200237.	1.5	5
10	Tumor Histological Grade and Immunotherapy Response in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2022, 148, 540.	1.2	2
11	Interrogation of T Cellâ€”enriched Tumors Reveals Prognostic and Immunotherapeutic Implications of Polyamine Metabolism. <i>Cancer Research Communications</i> , 2022, 2, 639-652.	0.7	2
12	An Immunogenomic Investigation of Oral Cavity Squamous Cell Carcinoma in Patients Aged 45â€”Years and Younger. <i>Laryngoscope</i> , 2021, 131, 304-311.	1.1	14
13	Bloodâ€”based biomarkers of human papillomavirusâ€”associated cancers: A systematic review and metaâ€”analysis. <i>Cancer</i> , 2021, 127, 850-864.	2.0	24
14	Treatment decision-making among patients with oropharyngeal squamous cell cancer: A qualitative study. <i>Oral Oncology</i> , 2021, 112, 105044.	0.8	14
15	Timing, number, and type of sexual partners associated with risk of oropharyngeal cancer. <i>Cancer</i> , 2021, 127, 1029-1038.	2.0	41
16	Predicting Adverse Histopathology and Need for Postsurgical Adjuvant Therapy for Human Papilloma Virusâ€”Associated Oropharynx Carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2021, 165, 309-316.	1.1	5
17	Assessment Criteria and Clinical Implications of Extranodal Extension in Head and Neck Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 265-278.	1.8	35
18	Impact of surgical margins on local control in patients undergoing <sc>singleâ€”modality</sc> transoral robotic surgery for <sc>HPVâ€”related</sc> oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2021, 43, 2434-2444.	0.9	20

#	ARTICLE	IF	CITATIONS
19	Factors and Outcomes Associated With Temporal Bone Resection for Primary Parotid Malignancy. <i>Laryngoscope</i> , 2021, 131, E2461-E2468.	1.1	3
20	Oncologic outcomes of human papillomavirus-associated oropharynx carcinoma treated with surgery alone: A 12-institution study of 344 patients. <i>Cancer</i> , 2021, 127, 3092-3106.	2.0	13
21	Radiation Therapy After Surgical Resection Improves Outcomes for Patients With Recurrent Pleomorphic Adenoma. <i>Advances in Radiation Oncology</i> , 2021, 6, 100674.	0.6	3
22	RTOG 0129 risk groups are reproducible in a prospective multicenter heterogeneously treated cohort. <i>Cancer</i> , 2021, 127, 3523-3530.	2.0	1
23	Comparison of new magnetic resonance imaging grading system with conventional endoscopy for the early detection of nasopharyngeal carcinoma. <i>Cancer</i> , 2021, 127, 3403-3412.	2.0	9
24	Epidemiologic distinctions between base of tongue and tonsil oropharyngeal carcinomas. <i>Head and Neck</i> , 2021, 43, 3076-3085.	0.9	4
25	Concerns and Needs of Patients With Head and Neck Cancer in the COVID-19 Era. <i>OTO Open</i> , 2021, 5, 2473974X2110477.	0.6	3
26	Projected Association of Human Papillomavirus Vaccination With Oropharynx Cancer Incidence in the US, 2020-2045. <i>JAMA Oncology</i> , 2021, 7, e212907.	3.4	57
27	p16 immunohistochemistry for primary tumor detection in HPV-positive squamous cell carcinoma of unknown primary. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2021, 42, 103015.	0.6	3
28	Epidemiology of HPV Related Malignancies. <i>Seminars in Radiation Oncology</i> , 2021, 31, 286-296.	1.0	21
29	Biologic and behavioral associations of estrogen receptor alpha positivity in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2021, 121, 105461.	0.8	2
30	Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: A secondary analysis of NRG Oncology RTOG 0129 and 0522. <i>Head and Neck</i> , 2021, 44, 158.	0.9	3
31	Nutritional Status as a Predictive Biomarker for Immunotherapy Outcomes in Advanced Head and Neck Cancer. <i>Cancers</i> , 2021, 13, 5772.	1.7	25
32	Association of Tumor Site With the Prognosis and Immunogenomic Landscape of Human Papillomavirus-Related Head and Neck and Cervical Cancers. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2021, . .	1.2	8
33	Development of a web-based, patient-centered decision aid for oropharyngeal cancer treatment. <i>Oral Oncology</i> , 2021, 123, 105618.	0.8	12
34	Tumor-infiltrating lymphocyte quantification stratifies early-stage human papillomavirus oropharynx cancer prognosis. <i>Laryngoscope</i> , 2020, 130, 930-938.	1.1	24
35	From presumed benign neck masses to delayed recognition of human papillomavirus-positive oropharyngeal cancer. <i>Laryngoscope</i> , 2020, 130, 392-397.	1.1	6
36	Computed tomography performance in predicting extranodal extension in HPV-positive oropharynx cancer. <i>Laryngoscope</i> , 2020, 130, 1479-1486.	1.1	26

#	ARTICLE	IF	CITATIONS
37	Drain placement in thyroidectomy is associated with longer hospital stay without preventing hematoma. <i>Laryngoscope</i> , 2020, 130, 1349-1356.	1.1	13
38	Survivorship support in head and neck cancer: American Head and Neck Society survey. <i>Head and Neck</i> , 2020, 42, 939-944.	0.9	11
39	Distinct biomarker and behavioral profiles of human papillomavirus-related oropharynx cancer patients by age. <i>Oral Oncology</i> , 2020, 101, 104522.	0.8	19
40	Paraganglioma of the recurrent laryngeal nerve. <i>Laryngoscope</i> , 2020, 130, E782-E785.	1.1	4
41	Long-term Persistence of Oral HPV Over 7 Years of Follow-up. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa047.	1.4	28
42	Unique role of HPV16 in predicting oropharyngeal cancer risk more than other oncogenic oral HPV infections. <i>Oral Oncology</i> , 2020, 111, 104981.	0.8	5
43	HPV-positive Squamous Cell Carcinoma of the Larynx, Oral Cavity, and Hypopharynx. <i>American Journal of Surgical Pathology</i> , 2020, 44, 691-702.	2.1	19
44	Considerations in Human Papillomavirus-Associated Oropharyngeal Cancer Screening. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2020, 146, 656.	1.2	13
45	The role of head and neck cancer advocacy organizations during the COVID-19 pandemic. <i>Head and Neck</i> , 2020, 42, 1526-1532.	0.9	8
46	Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI. <i>Oral Oncology</i> , 2020, 108, 104736.	0.8	40
47	Transcervical sonography and human papillomavirus 16 E6 antibodies are sensitive for the detection of oropharyngeal cancer. <i>Cancer</i> , 2020, 126, 2658-2665.	2.0	11
48	The Role of Age and Merkel Cell Polyomavirus in Oral Cavity Cancers. <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 163, 1194-1197.	1.1	5
49	Risk factors for human papillomavirus-positive nonoropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2020, 42, 1954-1962.	0.9	6
50	Burden of comorbidities is higher among elderly survivors of oropharyngeal cancer compared with controls. <i>Cancer</i> , 2020, 126, 1793-1803.	2.0	14
51	Reply to Survivors of cancer despite poor quality of care are heroes. <i>Cancer</i> , 2020, 126, 3373-3374.	2.0	0
52	Deintensification of treatment for human papillomavirus-related oropharyngeal cancer: Current state and future directions. <i>Oral Oncology</i> , 2020, 105, 104652.	0.8	60
53	We Survived 2020 With Patient Survivors. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2020, 146, 1097.	1.2	2
54	Factors to Consider When Contemplating Posttreatment Surveillance for Survivors of HPV-Associated Oropharyngeal Squamous Cell Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2019, 145, 908.	1.2	1

#	ARTICLE	IF	CITATIONS
55	Quality of care and short and long-term outcomes of oropharyngeal cancer care in the elderly. <i>Head and Neck</i> , 2019, 41, 3542-3550.	0.9	5
56	Evaluating the Utility and Prevalence of HPV Biomarkers in Oral Rinses and Serology for HPV-related Oropharyngeal Cancer. <i>Cancer Prevention Research</i> , 2019, 12, 689-700.	0.7	32
57	Association Between Hospital Market Concentration and Costs of Laryngectomy. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2019, 145, 939.	1.2	5
58	The prognostic impact of pathologic lymph nodes in HPV-positive oropharyngeal cancers. <i>Oral Oncology</i> , 2019, 89, 23-29.	0.8	6
59	Sex differences in HPV immunity among adults without cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1935-1941.	1.4	13
60	Priorities of human papillomavirus-associated oropharyngeal cancer patients at diagnosis and after treatment. <i>Oral Oncology</i> , 2019, 95, 11-15.	0.8	19
61	Association of Oral Human Papillomavirus DNA Persistence With Cancer Progression After Primary Treatment for Oral Cavity and Oropharyngeal Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2019, 5, 985.	3.4	71
62	Validation of NRG oncology/RTOGâ€œ129 risk groups for HPVâ€œpositive and HPVâ€œnegative oropharyngeal squamous cell cancer: Implications for riskâ€œbased therapeutic intensity trials. <i>Cancer</i> , 2019, 125, 2027-2038.	2.0	58
63	Tobacco Treatment Programs at National Cancer Institute-designated Cancer Centers. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 407-410.	0.6	11
64	To kiss or not to kiss in the era of the human papillomavirusâ€œassociated head and neck cancer â€œepidemicâ€œ?. <i>Laryngoscope</i> , 2019, 129, 4-5.	1.1	2
65	The Impact of a Stepwise Approach to Primary Tumor Detection in Squamous Cell Carcinoma of the Neck With Unknown Primary. <i>Laryngoscope</i> , 2019, 129, 1610-1616.	1.1	30
66	Association of Hospital Volume With Laryngectomy Outcomes in Patients With Larynx Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2019, 145, 62.	1.2	53
67	Prevalence of comorbidities and effect on survival in survivors of human papillomavirusâ€œrelated and human papillomavirusâ€œunrelated head and neck cancer in the United States. <i>Cancer</i> , 2019, 125, 249-260.	2.0	32
68	Priorities, concerns, and regret among patients with head and neck cancer. <i>Cancer</i> , 2019, 125, 1281-1289.	2.0	61
69	Effects of a Comprehensive Performance Improvement Strategy on Postoperative Adverse Events in Head and Neck Surgery. <i>Otolaryngology - Head and Neck Surgery</i> , 2019, 160, 799-809.	1.1	1
70	The prevalence of human papillomavirus in oropharyngeal cancer is increasing regardless of sex or race, and the influence of sex and race on survival is modified by human papillomavirus tumor status. <i>Cancer</i> , 2019, 125, 761-769.	2.0	69
71	Prevalence of Comorbidities among Older Head and Neck Cancer Survivors in the United States. <i>Otolaryngology - Head and Neck Surgery</i> , 2019, 160, 85-92.	1.1	39
72	Screening for human papillomavirusâ€œdriven oropharyngeal cancer: Considerations for feasibility and strategies for research. <i>Cancer</i> , 2018, 124, 1859-1866.	2.0	48

#	ARTICLE	IF	CITATIONS
73	Evaluating oropharyngeal carcinoma with transcervical ultrasound, CT, and MRI. <i>Oral Oncology</i> , 2018, 78, 177-185.	0.8	13
74	Short- and long-term outcomes of oropharyngeal cancer care in the elderly. <i>Laryngoscope</i> , 2018, 128, 2084-2093.	1.1	16
75	Head and neck squamous cell cancers in the United States are rare and the risk now is higher among white individuals compared with black individuals. <i>Cancer</i> , 2018, 124, 2125-2133.	2.0	38
76	Reader performance in the ultrasonographic evaluation of oropharyngeal carcinoma. <i>Oral Oncology</i> , 2018, 77, 105-110.	0.8	4
77	Sensitivity and specificity of oral HPV detection for HPV-positive head and neck cancer. <i>Oral Oncology</i> , 2018, 77, 52-56.	0.8	54
78	Quality indicators of oropharyngeal cancer care in the elderly. <i>Laryngoscope</i> , 2018, 128, 2312-2319.	1.1	3
79	Increasing prevalence of human papillomavirus-positive oropharyngeal cancers among older adults. <i>Cancer</i> , 2018, 124, 2993-2999.	2.0	111
80	Age Profile of Patients With Oropharyngeal Squamous Cell Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2018, 144, 538.	1.2	23
81	Prognostic factors for human papillomavirus-positive and negative oropharyngeal carcinomas. <i>Laryngoscope</i> , 2018, 128, E288-E296.	1.1	20
82	Pilot randomized controlled trial of a comprehensive smoking cessation intervention for patients with upper aerodigestive cancer undergoing radiotherapy. <i>Head and Neck</i> , 2018, 40, 1534-1547.	0.9	10
83	Treatment, survival, and costs of oropharyngeal cancer care in the elderly. <i>Laryngoscope</i> , 2018, 128, 1103-1112.	1.1	6
84	Effects of biodegradable hydrogel spacer injection on contralateral submandibular gland sparing in radiotherapy for head and neck cancers. <i>Radiotherapy and Oncology</i> , 2018, 126, 96-99.	0.3	14
85	Oral sampling methods are associated with differences in immune marker concentrations. <i>Laryngoscope</i> , 2018, 128, E214-E221.	1.1	3
86	Utility of preoperative fine needle aspiration in parotid lesions. <i>Laryngoscope</i> , 2018, 128, 398-402.	1.1	48
87	Imbalance Between Clinical and Pathologic Staging in the Updated American Joint Commission on Cancer Staging System for Human Papillomavirus-Positive Oropharyngeal Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 217-219.	0.8	25
88	Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 3152-3161.	0.8	153
89	Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement Summary of the CAP Guideline. <i>Journal of Oncology Practice</i> , 2018, 14, 613-617.	2.5	12
90	In Regard to Bossi et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 669-670.	0.4	2

#	ARTICLE	IF	CITATIONS
91	Treatment preferences in human papillomavirus-associated oropharyngeal cancer. <i>Future Oncology</i> , 2018, 14, 2521-2530.	1.1	20
92	Oropharyngeal cancer is no longer a disease of younger patients and the prognostic advantage of Human Papillomavirus is attenuated among older patients: Analysis of the National Cancer Database. <i>Oral Oncology</i> , 2018, 83, 147-153.	0.8	65
93	Prospective evaluation of patient reported swallow function with the Functional Assessment of Cancer Therapy (FACT), MD Anderson Dysphagia Inventory (MDADI) and the Sydney Swallow Questionnaire (SSQ) in head and neck cancer patients. <i>Oral Oncology</i> , 2018, 84, 25-30.	0.8	10
94	HEY1 is expressed independent of NOTCH1 and is associated with poor prognosis in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2018, 82, 168-175.	0.8	12
95	P16 as a Prognostic Biomarker for Nonoropharyngeal Squamous Cell Cancers: Avatar or Mirage?. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1290-1291.	3.0	6
96	Emerging insights into recurrent and metastatic human papillomavirus-related oropharyngeal squamous cell carcinoma. <i>Laryngoscope Investigative Otolaryngology</i> , 2017, 2, 10-18.	0.6	54
97	Evaluation of proposed staging systems for human papillomavirus-related oropharyngeal squamous cell carcinoma. <i>Cancer</i> , 2017, 123, 1768-1777.	2.0	51
98	Human papillomavirus (HPV) 16 antibodies at diagnosis of HPV-related oropharyngeal cancer and antibody trajectories after treatment. <i>Oral Oncology</i> , 2017, 67, 77-82.	0.8	28
99	Significant changes in sexual behavior after a diagnosis of human papillomavirus-positive and human papillomavirus-negative oral cancer. <i>Cancer</i> , 2017, 123, 1156-1165.	2.0	37
100	The prognostic role of sex, race, and human papillomavirus in oropharyngeal and nonoropharyngeal head and neck squamous cell cancer. <i>Cancer</i> , 2017, 123, 1566-1575.	2.0	187
101	AHNS series: Do you know your guidelines? Management of head and neck cancer in the era of human papillomavirus: Educating our patients on human papillomavirus. <i>Head and Neck</i> , 2017, 39, 833-839.	0.9	7
102	Primary, secondary and tertiary prevention of human papillomavirus-driven head and neck cancers. <i>European Journal of Cancer</i> , 2017, 78, 105-115.	1.3	14
103	Molecular mechanisms of human papillomavirus-related carcinogenesis in head and neck cancer. <i>Microbes and Infection</i> , 2017, 19, 464-475.	1.0	49
104	Differences in the Prevalence of Human Papillomavirus (HPV) in Head and Neck Squamous Cell Cancers by Sex, Race, Anatomic Tumor Site, and HPV Detection Method. <i>JAMA Oncology</i> , 2017, 3, 169.	3.4	104
105	Quantitative Evaluation of Head and Neck Cancer Treatment-Related Dysphagia in the Development of a Personalized Treatment Deintensification Paradigm. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 1271-1278.	0.4	13
106	The role of human papillomavirus on the prognosis and treatment of oropharyngeal carcinoma. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 449-461.	2.7	37
107	Genomic alterations in human epidermal growth factor receptor 2 ( <i>HER2/ERBB2</i> ) in head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2017, 39, E15-E19.	0.9	12
108	Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 4057-4065.	0.8	124

#	ARTICLE	IF	CITATIONS
109	AHNS Series: Do you know your guidelines? Principles of radiation therapy for head and neck cancer: A review of the National Comprehensive Cancer Network guidelines. <i>Head and Neck</i> , 2016, 38, 987-992.	0.9	26
110	Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines. <i>International Journal of Cancer</i> , 2016, 139, 510-517.	2.3	19
111	Rising population of survivors of oral squamous cell cancer in the United States. <i>Cancer</i> , 2016, 122, 1380-1387.	2.0	45
112	Follicular dendritic cell sarcoma of the head and neck: Case report, literature review, and pooled analysis of 97 cases. <i>Head and Neck</i> , 2016, 38, E2241-9.	0.9	45
113	Disease-free survival after salvage therapy for recurrent oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, E1501-9.	0.9	37
114	The epidemiology of the human papillomavirus related to oropharyngeal head and neck cancer. <i>Laryngoscope</i> , 2016, 126, 894-900.	1.1	111
115	Carcinogenic human papillomavirus infection. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16086.	18.1	615
116	Patient experience and anxiety during and after treatment for an HPV-related oropharyngeal cancer. <i>Oral Oncology</i> , 2016, 60, 90-95.	0.8	27
117	Race Is Associated With Sexual Behaviors and Modifies the Effect of Age on Human Papillomavirus Serostatus Among Perimenopausal Women. <i>Sexually Transmitted Diseases</i> , 2016, 43, 231-237.	0.8	3
118	The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer. <i>Cancer</i> , 2016, 122, 2313-2323.	2.0	72
119	Health-related quality of life before and after head and neck squamous cell carcinoma: Analysis of the Surveillance, Epidemiology, and End Results Medicare Health Outcomes Survey linkage. <i>Cancer</i> , 2016, 122, 1861-1870.	2.0	22
120	Changes in Unknown Primary Squamous Cell Carcinoma of the Head and Neck at Initial Presentation in the Era of Human Papillomavirus. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016, 142, 223.	1.2	97
121	Whole-Genome Sequencing of Salivary Gland Adenoid Cystic Carcinoma. <i>Cancer Prevention Research</i> , 2016, 9, 265-274.	0.7	80
122	Association of Ultrasound Characteristics With Extranodal Extension in Metastatic Papillary Thyroid Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016, 142, 263.	1.2	9
123	Serum Antibodies to HPV16 Early Proteins Warrant Investigation as Potential Biomarkers for Risk Stratification and Recurrence of HPV-Associated Oropharyngeal Cancer. <i>Cancer Prevention Research</i> , 2016, 9, 135-141.	0.7	40
124	Understanding the impact of survival and human papillomavirus tumor status on timing of recurrence in oropharyngeal squamous cell carcinoma. <i>Oral Oncology</i> , 2016, 52, 97-103.	0.8	33
125	The value of follow-up <sup>18</sup> F-FDG PET/CT in the management and prognosis of patients with HPV-positive oropharyngeal squamous cell carcinoma. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2015, 59, 681-686.	0.9	17
126	MYB rearrangement and clinicopathologic characteristics in head and neck adenoid cystic carcinoma. <i>Laryngoscope</i> , 2015, 125, E292-9.	1.1	59



#	ARTICLE	IF	CITATIONS
127	The role of sexual behavior in head and neck cancer: implications for prevention and therapy. Expert Review of Anticancer Therapy, 2015, 15, 35-49.	1.1	67
128	The Rise of HPV-Positive Oropharyngeal Cancers in the United States. Cancer Prevention Research, 2015, 8, 9-11.	0.7	21
129	FDG PET/CT for Management and Assessing Outcomes of Squamous Cell Cancer of the Oral Cavity. American Journal of Roentgenology, 2015, 205, W150-W161.	1.0	31
130	Epigenetic screening of salivary gland mucoepidermoid carcinoma identifies hypomethylation of CLIC3 as a common alteration. Oral Oncology, 2015, 51, 1120-1125.	0.8	15
131	The Impact of Tonsillectomy upon the Risk of Oropharyngeal Carcinoma Diagnosis and Prognosis in the Danish Cancer Registry. Cancer Prevention Research, 2015, 8, 583-589.	0.7	38
132	Reduction of Pharyngocutaneous Fistulae in Laryngectomy Patients by a Comprehensive Performance Improvement Intervention. Otolaryngology - Head and Neck Surgery, 2015, 153, 927-934.	1.1	4
133	Cleaved NOTCH1 Expression Pattern in Head and Neck Squamous Cell Carcinoma Is Associated with NOTCH1 Mutation, HPV Status, and High-Risk Features. Cancer Prevention Research, 2015, 8, 287-295.	0.7	43
134	Reply to B. O'Sullivan et al. Journal of Clinical Oncology, 2015, 33, 1708-1709.	0.8	11
135	Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Science Translational Medicine, 2015, 7, 293ra104.	5.8	372
136	Increase in head and neck cancer in younger patients due to human papillomavirus (HPV). Oral Oncology, 2015, 51, 727-730.	0.8	168
137	Surgical salvage improves overall survival for patients with HPV-positive and HPV-negative recurrent locoregional and distant metastatic oropharyngeal cancer. Cancer, 2015, 121, 1977-1984.	2.0	116
138	Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2015, 21, 30-38.	3.2	158
139	Intrathrapy or Posttherapy FDG PET or FDG PET/CT for Patients With Head and Neck Cancer: A Systematic Review and Meta-analysis of Prognostic Studies. American Journal of Roentgenology, 2015, 205, 1102-1113.	1.0	22
140	Oropharyngeal cancer survivorship in Denmark, 1977-2012. Oral Oncology, 2015, 51, 982-984.	0.8	18
141	Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. Journal of Clinical Oncology, 2015, 33, 3235-3242.	0.8	873
142	Prognostic Implication of Persistent Human Papillomavirus Type 16 DNA Detection in Oral Rinses for Human Papillomavirus-Related Oropharyngeal Carcinoma. JAMA Oncology, 2015, 1, 907.	3.4	82
143	Diagnostic Accuracy of Follow-Up FDG PET or PET/CT in Patients With Head and Neck Cancer After Definitive Treatment: A Systematic Review and Meta-Analysis. American Journal of Roentgenology, 2015, 205, 629-639.	1.0	80
144	Visualization of the Oropharynx With Transcervical Ultrasound. American Journal of Roentgenology, 2015, 205, 1288-1294.	1.0	32

#	ARTICLE	IF	CITATIONS
145	Pharyngocutaneous fistula after total laryngectomy: A single-institution experience, 2001â€“2012. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2015, 36, 24-31.	0.6	39
146	Clinical, genomic, and metagenomic characterization of oral tongue squamous cell carcinoma in patients who do not smoke. Head and Neck, 2015, 37, 1642-1649.	0.9	66
147	Transcervical Ultrasonography Is Feasible to Visualize and Evaluate Base of Tongue Cancers. PLoS ONE, 2014, 9, e87565.	1.1	34
148	Differences in Oral Sexual Behaviors by Gender, Age, and Race Explain Observed Differences in Prevalence of Oral Human Papillomavirus Infection. PLoS ONE, 2014, 9, e86023.	1.1	173
149	Transcervical Ultrasound Identifies Primary Tumor Site of Unknown Primary Head and Neck Squamous Cell Carcinoma. Otolaryngology - Head and Neck Surgery, 2014, 151, 1090-1092.	1.1	17
150	Tobacco Use and Oral HPV-16 Infection. JAMA - Journal of the American Medical Association, 2014, 312, 1465.	3.8	66
151	The clinical impact of HPV tumor status upon head and neck squamous cell carcinomas. Oral Oncology, 2014, 50, 565-574.	0.8	207
152	Incidence and risk factors of HPV-related and HPV-unrelated Head and Neck Squamous Cell Carcinoma in HIV-infected individuals. Oral Oncology, 2014, 50, 1169-1176.	0.8	77
153	Human Papillomavirus and Overall Survival After Progression of Oropharyngeal Squamous Cell Carcinoma. Journal of Clinical Oncology, 2014, 32, 3365-3373.	0.8	449
154	HPV and head and neck cancers: State-of-the-science. Oral Oncology, 2014, 50, 353-355.	0.8	32
155	The use of ultrasound in the search for the primary site of unknown primary head and neck squamous cell cancers. Oral Oncology, 2014, 50, 640-645.	0.8	44
156	Comparison of the immune microenvironment of the oral cavity and cervix in healthy women. Cytokine, 2013, 64, 597-604.	1.4	23
157	Long-term prognosis and risk factors among patients with HPV-associated oropharyngeal squamous cell carcinoma. Cancer, 2013, 119, 3462-3471.	2.0	86
158	Discussing the diagnosis of HPV-OSCC: Common questions and answers. Oral Oncology, 2013, 49, 863-871.	0.8	71
159	Transoral Robotic Surgery Experience in 44 Cases. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2013, 23, 900-907.	0.5	36
160	The Effect of tumor subsite on short-term outcomes and costs of care after oral cancer surgery. Laryngoscope, 2013, 123, 1652-1659.	1.1	22
161	Robotic-Assisted Neck Dissection Through a Pre- and Post-auricular Hairline Incision: Preclinical Study. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2012, 22, 791-796.	0.5	9
162	Neck dissection through a facelift incision. Laryngoscope, 2012, 122, 2700-2706.	1.1	22

#	ARTICLE	IF	CITATIONS
163	Long-term survival of a patient with leptomeningeal involvement by nasopharyngeal carcinoma after treatment with high-dose intravenous methotrexate. <i>Head and Neck</i> , 2012, 34, 296-300.	0.9	2
164	Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in <i>NOTCH1</i> . <i>Science</i> , 2011, 333, 1154-1157.	6.0	1,568
165	The prevalence, diagnosis, and management of voice disorders in a National Ambulatory Medical Care Survey (NAMCS) cohort. <i>Laryngoscope</i> , 2011, 121, 150-157.	1.1	36
166	Associations between Oral HPV16 Infection and Cytopathology: Evaluation of an Oropharyngeal Pap-Test Equivalent in High-Risk Populations. <i>Cancer Prevention Research</i> , 2011, 4, 1378-1384.	0.7	139
167	Integrated, Genome-Wide Screening for Hypomethylated Oncogenes in Salivary Gland Adenoid Cystic Carcinoma. <i>Clinical Cancer Research</i> , 2011, 17, 4320-4330.	3.2	68
168	Two-Week versus Six-Month Sampling Interval in a Short-Term Natural History Study of Oral HPV Infection in an HIV-Positive Cohort. <i>PLoS ONE</i> , 2010, 5, e11918.	1.1	36
169	Improved Survival of Patients With Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical Trial. <i>Journal of the National Cancer Institute</i> , 2008, 100, 261-269.	3.0	2,397
170	Case-Control Study of Human Papillomavirus and Oropharyngeal Cancer. <i>New England Journal of Medicine</i> , 2007, 356, 1944-1956.	13.9	2,345
171	Six-month natural history of oral versus cervical human papillomavirus infection. <i>International Journal of Cancer</i> , 2007, 121, 143-150.	2.3	160
172	Clinical Implications of Human Papillomavirus in Head and Neck Cancers. <i>Journal of Clinical Oncology</i> , 2006, 24, 2606-2611.	0.8	432
173	Relationship between Prevalent Oral and Cervical Human Papillomavirus Infections in Human Immunodeficiency Virus-Positive and -Negative Women. <i>Journal of Clinical Microbiology</i> , 2006, 44, 4479-4485.	1.8	120
174	ABCs of Cardiovascular Disease Risk Management. <i>Cardiology in Review</i> , 2001, 9, 96-105.	0.6	17
175	Biomarker-Based Evaluation of Treatment Response and Surveillance of HPV-Associated Squamous Cell Carcinoma. <i>Current Otorhinolaryngology Reports</i> , 0, , 1.	0.2	1
176	Volume-Based Versus Mortality-Based Standards for Surgical Quality: Both Risk Adjustment and Volume Matter. <i>Journal of Clinical Oncology</i> , 0, , .	0.8	1